Elevate

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Zivian targets $13-to-$1 chart review gap as healthcare oversight moves to AI

Zivian Health’s Elevate platform automates chart selection, physician review workflows and compliance records while using AI to surface clinical patterns, targeting an oversight problem that becomes harder as nurse practitioner and physician assistant workforces expand.

bySrinath

October 7, 2026

Elevate acquires Downstream and GA to build global creative studio for sports, brands, and hospitality

Elevate consolidates Downstream and GA in global design push to lead sports, brand, and hospitality experiences

Elevate has acquired Downstream and GA to form a unified global studio for experience design. Find out how this move reshapes creative agency competition.

byVenkatesh

December 19, 2025

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Zivian targets $13-to-$1 chart review gap as healthcare oversight moves to AI

Elevate consolidates Downstream and GA in global design push to lead sports, brand, and hospitality experiences

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

SAMILBIO expands Chaeyun skincare with two November launches as K-beauty exports reach $11.1bn

Schneider Electric Infrastructure (SCHNEIDER) shares fall 3.5% despite new factory expansion: What will November results reveal?

Haleon (HLN) near 319p: Does a 15% share-price crash make its valuation attractive after the growth downgrade?

Ethan Allen will split CEO and chair roles, but who gets to choose Farooq Kathwari’s successor?